Kala Pharmaceuticals

Latest Headlines

Latest Headlines

Kala reels in $22.5M to get its next-gen eye drops into PhIII

Kala Pharmaceuticals, co-founded by MIT biotech luminary Robert Langer, has closed a $22.5 million B round, cash the company says will help advance its novel approach to eye treatments.

The 2013 Fierce 15 biotech execs take a bow

Our annual Fierce 15 report on a top class of up-and-coming private biotechs came out today and I wanted to highlight the responses from many of the companies which are on the list. Read more | Check out this year's report

FierceBiotech's 2013 Fierce 15

Last year when Ryan McBride and I were sorting through our short list of candidates, we both felt that Seaside Therapeutics deserved a spot on the list. The small company had raised a considerable...

Langer's Kala touts positive results for topical wet AMD treatment

Kala Pharmaceuticals is developing a novel way to get drugs into the eye, and the company notched some positive results in preclinical studies, finding that its platform led to higher drug concentration for a retinal treatment.

Entrega, other startups make strides in needle-free delivery

Boston startup Entrega is developing a novel drug-delivery capsule that could give the company a foothold in a $200 billion arena just begging for more needle-free options, paving the way for the more elegant delivery of treatments for diseases such as Parkinson's, cancer and arthritis.

Langer biotech Kala earmarks $11.5M round for next-gen ophthalmology drugs

The new CEO at Kala Pharmaceuticals has landed an $11.5 million A round and mapped out plans to devote much of the cash to lead programs on wet, age-related macular degeneration and ocular inflammation.

Langer's Kala scores Cystic Fibrosis Foundation grant

Kala Pharmaceuticals received a grant from the Cystic Fibrosis Foundation to demonstrate that the company's mucosal-barrier-penetrating nanoparticle can do the same across bacterial biofilms, a symptom of cystic fibrosis.

Targacept taps Stephen A. Hill to serve as president and CEO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Ex-Sanofi exec takes helm at Bob Langer startup

Mucosal delivery company Kala Pharmaceuticals has welcomed Guillaume Pfefer, ex-general manager of Sanofi Pasteur Mexico, as its new president and CEO. Kala's co-founder, Justin Hanes, has published data on the company's mucosal-penetrating products (MPPs) in Science Translational Medicine.

New Kala CEO plans to raise funds for particle tech programs

The startup biotech Kala Pharmaceuticals has taken another step forward in its journey to the clinic. The Waltham, MA-based developer of mucus-penetrating particle treatments--one of Robert Langer's portfolio of startups--has wooed Gillaume Pfeffer into the top spot.